wr 1065 has been researched along with Mucositis, Oral in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bachy, CM; Cassatt, DR; Fazenbaker, CA; Kifle, G | 1 |
| Bachy, CM; Cassatt, DR; Fazenbaker, CA; Kifle, G; McCarthy, MP | 1 |
2 other study(ies) available for wr 1065 and Mucositis, Oral
| Article | Year |
|---|---|
Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model.
Topics: Amifostine; Animals; Female; Injections, Intravenous; Injections, Subcutaneous; Mercaptoethylamines; Models, Animal; Mouth Mucosa; Radiation Injuries; Radiation-Protective Agents; Rats; Rats, Sprague-Dawley; Stomatitis; Xerostomia | 2003 |
Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure.
Topics: Amifostine; Animals; Dose Fractionation, Radiation; Drug Evaluation, Preclinical; Female; Injections, Intravenous; Injections, Subcutaneous; Mammary Neoplasms, Experimental; Mercaptoethylamines; Mouth Mucosa; Radiation Injuries, Experimental; Radiation-Protective Agents; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Stomatitis; Tissue Distribution | 2005 |